Background: Off-label prescribing is encountered across various fields of medicine and
| INTRODUCTION
Off-label drug prescribing is widespread in daily clinical practice and includes the use of drugs outside the licensed indication, dosage, route of administration or age. 1 Examples of widely prescribed off-label drugs include the use of beta-blockers for anxiety, tricyclic antidepressants for chronic pain and oral contraception to treat endometriosis or acne.
Off-label drugs may create alternative therapeutic options, but have also been associated with safety risks since they are underevaluated for unlicensed indications. 2 A lack of drug approval by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) generally means a shortage of scientific scrutiny as compared to labelled indications. 3 In a large Canadian cohort, the rate of preventable adverse drug reactions was considerably higher in off-label prescriptions (19.7 per 10 000 person-months) as compared to on-label prescriptions (12.5 per 10 000 person-months). 2 Although off-label prescribing is legal and common in most countries, physicians carry primary responsibility for accurately prescribing and monitoring therapy with off-label drugs, as acknowledged by the Medicines Healthcare product Regulatory Agency (MHRA) and the General Medical Council (GMC) in the United Kingdom (UK). 4, 5 Several studies reported on the inadequate awareness of off-label drugs by physicians and patients. In a survey among 600 physicians in the US, 45% was unaware of the FDA status of the medications they prescribed. 6 In a teaching hospital in India, two-thirds of the residents had insufficient knowledge on unlicensed drugs, and onethird assumed that off-label prescribing was not legal. 7 The use of off-label drugs seems to vary between different fields of medicine. In the intensive care unit and paediatrics, off-label prescription rates were up to 36% and 62%, respectively. 8, 9 In oncology, off-label drug prescriptions were in the range of 18%-41% for hospitalised cancer patients and 7%-50% for ambulatory care patients. 10 In the largest cohort study among office-based physicians, an estimated 21% of overall prescriptions (725 million) were off-label. 11 In the treatment of inflammatory bowel diseases (IBD), off-label drugs are prescribed as well, especially in patients who failed standard treatment regimens. The overall magnitude of off-label prescribing for Crohn's disease and ulcerative colitis is unknown. To provide optimal therapeutic care, a better understanding of off-label drug prescriptions in this field is needed. We aimed to assess the proportion and characteristics of off-label prescribing for IBD.
| ME TH ODS

| Study design and population
We performed a retrospective analysis of prospectively collected data from the Dutch IBD Biobank. This is a nationwide biobank in which data and biomaterial of adult IBD patients are routinely collected from all seven Dutch university medical centres in the Nether- All adult patients enrolled in the Dutch IBD Biobank with available data on current and historical drug prescriptions for the treatment of IBD were included in the study. Duplications were excluded from the analysis. When it was uncertain whether the unapproved drug was prescribed for IBD or another indication, this prescription was excluded from the off-label analysis as well.
| Off-label drugs
Drugs which were unlicensed for Crohn's disease and/or ulcerative colitis by the Dutch Medicines Evaluation Board (MEB) were classified as off-label. 13, 14 These off-label drugs are depicted in Table 1 .
Patients with IBD unclassified or IBD indeterminate were included in the ulcerative colitis group, or in case of a re-classification during the disease course, in the group according to the most recent IBD diagnosis. Drugs used in addition to the primary IBD medications, for example supplements or medication for symptom management, were disregarded from the analysis. This also included antibiotics, because we could not identify the precise indications for antibiotic treatment in the nationwide IBD database. In the Netherlands, thioguanine, an alternative thiopurine-derivative, has been conditionally licensed as a certified IBD treatment since mid-2015. 15 Because thioguanine was relicensed recently and solely in the Netherlands, we considered this drug off-label for this study.
| Data collection
Outcome measures were (a) the proportion of IBD patients exposed to off-label drugs and (b) the rate of off-label drug prescriptions for IBD.
Collected data included patient demographics, IBD phenotype according to Montreal classification, 16 disease duration, surgical history, smoking habits and current and historical drug prescriptions for IBD. Crohn's disease or ulcerative colitis are depicted in Table 2 .
| Statistics
| Patient characteristics
There was no difference in gender ratio between patients with (n = 1477) and without (n = 3106) off-label prescriptions for the treatment of IBD (Table 2 ). Off-label drug users were slightly older at time of diagnosis (30 ± 13 vs 29 ± 13, P = 0.019) and had a shorter median IBD disease duration (16, IQR: 10 -24 vs 18, IQR:
12 -27), P < 0.001). In addition, patients who never smoked were less exposed to off-label drugs as compared to patients who were previous or current smokers (27% vs 33%, P < 0.001). These outcomes were similar for both ulcerative colitis and Crohn's disease.
| Disease characteristics
Use of off-label drugs was higher in patients with ulcerative colitis compared to Crohn's disease (37% vs 29%, P < 0.001). Both for ulcerative colitis and Crohn's disease, there were no phenotypic differences according to the Montreal classification between patients with and without off-label IBD prescriptions. Furthermore, there were no differences in the number of IBD-related surgeries including pouch rates between off-label drug users and non-users. The rates of stoma, however, were higher in the IBD group without off-label drug exposure (10% vs 7%, P = 0.001).
| Off-label drugs
A total of 12 651 historical and current drug records for the induction or maintenance treatment of 4583 IBD patients were available in the database. Of these, 2374 (19%) considered prescriptions which were off-label for Crohn's disease and/or ulcerative colitis. The prevalence of the prescribed off-label drugs for Crohn's disease and ulcerative colitis are summarised in Figure 1 .
Overall, the most commonly prescribed off-label drugs for IBD in the whole cohort were mercaptopurine (822/4583, 18%) and beclomethasone (529/4583, 12%). Furthermore, thioguanine was prescribed in 168 (4%) and allopurinol in 149 patients (3%).
Methotrexate, an immunomodulator which is only off-label for the treatment of ulcerative colitis, was prescribed in 71 patients (2%).
Other less traditional (non-thiopurine/methotrexate) off-label drugs for the treatment of Crohn's disease or ulcerative colitis were prescribed in 243 patients (6%). The patient and treatment characteristics of this specific group are depicted in 
| Multiple drug use (≥ 5) during IBD course
Patients who used multiple drugs during their IBD disease course, defined as at least five different drugs, were more likely to receive off-label drugs (66% vs 22%, P < 0.001). This association appeared to be stronger in ulcerative colitis (69% of patients with multiple drug use were treated with off-label drugs) than in Crohn's disease (53% of patients with multiple drug use were treated with off-label drugs).
| Determinants of off-label prescribing
Several determinants were associated with increased off-label prescribing as presented in 
| DISCUSSION
In this nationwide IBD cohort of all Dutch university hospitals, 32% of patients were exposed to off-label drugs and 19% of all prescriptions were off-label. Patients with ulcerative colitis were more likely to receive off-label drugs compared to patients with Crohn's disease.
Off-label prescriptions were also more common among smokers (in both Crohn's disease and ulcerative colitis) and patients who received at least 5 different drugs for IBD during their disease course. Age at diagnosis and having a stoma were only associated with off-label drugs in the univariate analyses.
Off-label prescribing is encountered across various fields of medicine. Unlike FDA or EMA labelled drugs, off-label drugs may lack scientific evidence and be associated with safety risks considering that they are under-evaluated for the unapproved indication. 2 Accountable use of (off-label) medicines has received growing attention in recent years. Also in the Netherlands, regulations for off-label prescriptions are more strictly regulated by the Dutch Medicines Act since 2007 due to safety concerns. 17 The regulations of off-label prescribing are not harmonised across the world. Even in Europe, each country has established its own regulations. 18 Comparing results on off-label prescribing between countries is therefore difficult, but the need of better understanding and proper prescribing of off-label drugs has been universally acknowledged.
In this Dutch cohort, mercaptopurine was the most frequently Thioguanine, a less-established thiopurine-derivative, was prescribed in 4% of all patients in this cohort. After being utilised as an off-label drug for IBD for years, thioguanine has been recently licensed conditionally for IBD in the Netherlands. 15 The relicensing of thioguanine was considered unique and important to accomplish safe application of this drug in IBD patients who previously failed azathioprine or mercaptopurine. Prospective registry studies are ongoing to gather additional data on efficacy and safety of thioguanine as a maintenance treatment for IBD before final evaluation. 21 Other frequently prescribed off-label drugs in this IBD cohort included beclomethasone (12%), ciclosporin (2%) and tacrolimus (2%).
Also considering these drugs, robust safety databases might be important to adequately determine the benefit-risk profile of these off-label therapies for the treatment of patients with IBD.
We observed a total rate of 19% off-label prescriptions for IBD T A B L E 3 IBD patients treated with off-label, non-conventional immunomodulating drugs Montreal: Age at diagnosis our cohort, however, we were unable to account for these drug characteristics. In the field of paediatrics, off-label prescription rates are considerable higher and rates go up to 80%. 22 Including the paediatric IBD population to our cohort would most likely have increased the proportion of off-label prescriptions substantially.
Ciclosporin Tacrolimus Mycophenolate Thalidomide Certolizumab Golimumab Natalizumab Tofacitinib Ustekinumab
In this study, we explored a poorly studied aspect of therapeutic IBD care using a nationwide database to provide an insight into offlabel prescribing for IBD. Our tertiary care population represents patients with complicated diseases who may have been at increased risk for being treated with drugs outside of the standard treatment regimen. Therefore, generalisation of these findings to the broader IBD population is not prudent. Another limitation of our study was that we strongly depend on the strength of data documentation at the site level. The information in the Dutch IBD Biobank is updated regularly (ie data are automatically uploaded from the local database to the central database at least once a month), still missing data or information bias might have been introduced in our study. 12 Moreover, we only investigated the prevalence of off-label IBD prescriptions and the proportion of patients exposed to these drugs, but we
were not able to assess further questions about the reasons for initiation and withdrawal of off-label drugs. Future research is needed to evaluate the considerations for, and knowledge about, off-label prescriptions and its safety and consequences for the treatment of IBD.
Another interesting issue would be the impact of costs of off-label prescriptions, as compared to novel costly pharmaceutical agents, on the treatment of IBD.
In conclusion, in a nationwide cohort consisting of tertiary IBD patients, about one-third was exposed to off-label drugs and onefifth of all IBD prescriptions were off-label. Off-label drug use was more common among patients with ulcerative colitis, smokers and patients who previously received at least five different IBD drugs during their disease course. 
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